Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENTANA: Metronomic Vinorelbine and Letrozole in Early Breast Cancer
NCT02802748Phase 1Completed
- Sponsor
- SOLTI
- Start
- Jul 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vinorelbine in breast cancer (3 arms), sponsored by SOLTI. Primary endpoint: Changes in the expression of the PAM50 proliferation signature at 3 weeks. Started Jul 2016; status: completed.
02
Drugs
vinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02802748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802748.